Live Quote · OTCHOOKHealthcare· Biotechnology

HOOKIPA Pharma Inc.

$1.15 0.00%(+$0.00)
TickerSpark Score
68/100
Solid
100
Valuation
40
Profitability
55
Growth
84
Health
60
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOOK research report →

52-Week Range46% of range
Low
$0.81
Current
$1.15
High
$1.55
Company Overviewwww.hookipapharma.com

About the company

HOOKIPA Pharma Inc. , a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer.

CEO
Malte Peters
IPO
2019
Employees
82
HQ
New York, NY, US

Price Chart

-6.50% · this period
$1.23$1.02$0.82Jul 02Dec 31Jul 02
Valuation
Market Cap
$14.40M
P/E
-0.32
P/S
1.42
P/B
0.51
EV/EBITDA
0.47
Div Yield
0.00%
Profitability
Gross Margin
100.00%
Op Margin
-453.11%
Net Margin
-415.28%
ROE
-110.98%
ROIC
-114.60%
Growth & Income
Revenue
$9.70M · -77.93%
Net Income
$-13,837,000 · 68.19%
EPS
$-1.09 · 68.59%
Op Income
$-36,572,000
FCF YoY
85.07%
Performance & Tape
52W High
$1.55
52W Low
$0.81
50D MA
$1.15
200D MA
$1.00
Beta
0.77
Avg Volume
11.96K

Get TickerSpark's AI analysis on HOOK

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Aug 19, 25Peters Maltesell25,172
Jul 22, 25Peters Maltesell29,176
Jul 22, 25Coelho Mary Theresasell13,609
Jul 22, 24Coelho Mary Theresaother69,875
Jul 22, 24Peters Malteother108,695
Jul 22, 24Cassidy Sean Aother9,800
Jul 22, 24Cassidy Sean Aother0
Jun 17, 24Peters Malteother49,000
Jun 17, 24van de Winkel Janother98,000
Jun 17, 24Kaufman David Rossother49,000
Coverage · HOOK

Our HOOK coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on HOOK yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate HOOK report →
Internal Compare

Similar companies

Peers in the same neighborhood.